European Journal of Neurology · 2024 · 10 citations · 11 references
MedicineInternal MedicinePharmacotherapyGeneral Internal MedicineGeriatricsImmunotherapyEnzyme DeficienciesMyopathy Evaluation10-Meter Walk Test6-Minute Walk TestEnzyme ActivityEnzyme Replacement TherapyPompe Disease PharmacotherapyRespiratory Muscle Involvement
INTRODUCTION: Late-onset Pompe disease (LOPD) is characterized by a progressive myopathy resulting from a deficiency of acid α-glucosidase enzyme activity. Enzyme replacement therapy has been shown to be effective, but long-term treatment results vary. Avalglucosidase alfa demonstrated non-inferiority to alglucosidase alfa in a phase 3 study, allowing in France compassionate access for advanced LOPD patients unresponsive to alglucosidase alfa. METHODS: Data from the French Pompe registry were analyzed for patients who benefited from a switch to avalglucosidase alfa with at least 1 year of follow-up. Respiratory (forced vital capacity [FVC]) and motor functions (Six-Minute Walk Test [6MWT]) were assessed before and 1 year after switching. Individual changes in FVC and 6MWT were expressed as slopes and statistical analyses were performed to compare values. RESULTS: Twenty-nine patients were included (mean age 56 years, 11 years of prior treatment). The FVC and 6MWT values remained stable. The individual analyses showed a stabilization of motor worsening: -1 m/year on the 6MWT after the switch versus -63 m/year the year before the switch (i.e., a worsening of 33%/year before vs. an improvement of 3%/year later). Respiratory data were not statistically different. DISCUSSION: At the group level, gait parameters improved slightly with a stabilization of previous worsening, but respiratory parameters showed limited changes. At the individual level, results were discordant, with some patients with a good motor or respiratory response and some with further worsening. CONCLUSION: Switching to avalglucosidase alfa demonstrated varied responses in advanced LOPD patients with failing alglucosidase alfa therapy, with a general improvement in motor stabilization.
11
Inhaled Iloprost for Severe Pulmonary Hypertension
Horst Olschewski, Gérald Simonneau, Nazzareno Galiè et al. · New England Journal of Medicine · 2002 · 1.8K citations · Full text
Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 184 citations · Full text
Yunxiang Zhu, Ji-Lei Jiang, Nathan Gumlaw et al. · Molecular Therapy · 2009 · 171 citations · Full text